این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Research in Pharmaceutical Sciences، جلد ۱۴، شماره ۴، صفحات ۳۰۸-۳۱۹
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Nicotine, as a novel tolerogenic adjuvant, enhances the efficacy of immunotherapy in a mouse model of allergic asthma
چکیده انگلیسی مقاله An increasing trend in the incidence of allergic diseases including asthma and related morbidity and mortality is observed worldwide during the last decades. Allergen-specific immunotherapy is suggested for the treatment of some allergic diseases; nevertheless, there is always a menace of uncommon, but life-treating reactions due to increasing the administration of allergen extract doses. Hence, improving its efficacy may reduce the required doses as well as the risk of such reactions. The current study aimed at examining the effects of nicotine (NIC), as a tolerogenic adjuvant, on the improvement of immunotherapy efficacy in a mouse model of allergic asthma. BALB/c mice were sensitized using alum and ovalbumin (OVA) on the days 0 and 7. Mice received OVA either alone or together with NIC (1 or 10 mg/kg) on the days 21, 23, and 25. Then, the mice were challenged with OVA 5% using a nebulizer on the days 35, 38, and 41 and sacrificed the next day. Co-administration of OVA and NIC decreased the inflammation of the lung tissue, eosinophils count in the bronchoalveolar lavage (BAL) fluid, the serum level of OVA-specific immunoglobulin E, as well as interleukin (IL)-4 production, while increasing the population of antigen-specific regulatory T-cells (Treg cells) and transforming growth factor-β/IL-4(TGF-β/IL-4) ratio compared to the OVA and control groups in a dose-dependent manner. Collectively, the findings suggest that administration of NIC plus the allergen increased immunotherapy efficacythrough decreasing allergic inflammation and allergic responses intensity, and increasingTreg cells population.
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله | Ebrahim Mazloomi
2Department of Pathology, School of Medicine, Urmia University of Medical Sciences, Urmia, I.R. Iran.


| Behrooz Ilkhanizadeh
3Immunology, Asthma and Allergy Research Institute, Tehran University of Medical sciences, Tehran, I.R. Iran.


| Ahad Zare
4Department of Genetics and Immunology, School of Medicine, Urmia University of Medical Sciences, Urmia, I.R. Iran.


| Adel Mohammadzadeh
5Department of Cellular and Molecular Biotechnology, Institute of Biotechnology, Urmia University, Urmia, I.R. Iran.


| Nowruz Delirezh
1Cellular and Molecular Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, I.R. Iran.


| Shahram Shahabi


نشانی اینترنتی http://rps.mui.ac.ir/index.php/jrps/article/view/1909
فایل مقاله اشکال در دسترسی به فایل - ./files/site1/rds_journals/115/article-115-1870954.pdf
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده Original Article
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات